In the field of CVD associated with metabolic pathologies, promising results have been reported for glucagon-like peptide-1 (GLP-1), an endogenous insulin secretagogue that increases glucose utilization in the heart, globally improving cardiac function after acute myocardial infarction [238]. This evidence concerns the gene GCG and myocardial infarction.